Cargando…
The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxidized low-density lipoprotein (oxLDL) is a promising therapeutical target in a wide range of metabolic diseases. In mice, pneumococcal immunization increases anti-phosphorylcholine and oxLDL antibody levels, an...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831333/ https://www.ncbi.nlm.nih.gov/pubmed/33477615 http://dx.doi.org/10.3390/antiox10010129 |
_version_ | 1783641612836929536 |
---|---|
author | Shiri-Sverdlov, Ronit dos Reis, Inês Magro Oligschlaeger, Yvonne Hendrikx, Tim Meesters, Dennis M. Vanclooster, Annick Vanhoutvin, Nele Koek, Ger H. Westerterp, Marit Binder, Christoph J. Cassiman, David Houben, Tom |
author_facet | Shiri-Sverdlov, Ronit dos Reis, Inês Magro Oligschlaeger, Yvonne Hendrikx, Tim Meesters, Dennis M. Vanclooster, Annick Vanhoutvin, Nele Koek, Ger H. Westerterp, Marit Binder, Christoph J. Cassiman, David Houben, Tom |
author_sort | Shiri-Sverdlov, Ronit |
collection | PubMed |
description | As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxidized low-density lipoprotein (oxLDL) is a promising therapeutical target in a wide range of metabolic diseases. In mice, pneumococcal immunization increases anti-phosphorylcholine and oxLDL antibody levels, and reduces atherosclerosis, non-alcoholic steatohepatitis and Niemann–Pick disease burden. These findings suggest that pneumococcal vaccination may be a useful preventive and therapeutical strategy in metabolic disease patients. In this pilot clinical trial, our aim was to determine whether the administration of a pneumococcal vaccine increases anti-phosphorylcholine and anti-oxLDL antibody levels in metabolic disease patients. The following patients were enrolled: four patients with familial partial lipodystrophy (all women, mean age 32 years old); three familial hypercholesterolemia patients (one girl, two boys; mean age 13 years); and two Niemann–Pick type B (NP-B) patients (two men, mean age 37.5 years old). Participants received one active dose of a 13-valent conjugated pneumococcal vaccine (Prevenar 13) and were followed-up for four weeks. Four weeks after Prevenar 13 vaccination, no differences were observed in patients’ levels of anti-oxLDL IgM or IgG antibodies. In addition, we observed a reduction in anti-phosphorylcholine (anti-PC) IgM antibody levels, whereas no differences were observed in anti-PC IgG antibody titers. These findings indicate that Prevenar 13 vaccination does not induce an immune response against oxLDL in patients with metabolic diseases. Therefore, Prevenar 13 is not suited to target the metabolic disruptor and pro-inflammatory mediator oxLDL in patients. |
format | Online Article Text |
id | pubmed-7831333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78313332021-01-26 The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial Shiri-Sverdlov, Ronit dos Reis, Inês Magro Oligschlaeger, Yvonne Hendrikx, Tim Meesters, Dennis M. Vanclooster, Annick Vanhoutvin, Nele Koek, Ger H. Westerterp, Marit Binder, Christoph J. Cassiman, David Houben, Tom Antioxidants (Basel) Article As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxidized low-density lipoprotein (oxLDL) is a promising therapeutical target in a wide range of metabolic diseases. In mice, pneumococcal immunization increases anti-phosphorylcholine and oxLDL antibody levels, and reduces atherosclerosis, non-alcoholic steatohepatitis and Niemann–Pick disease burden. These findings suggest that pneumococcal vaccination may be a useful preventive and therapeutical strategy in metabolic disease patients. In this pilot clinical trial, our aim was to determine whether the administration of a pneumococcal vaccine increases anti-phosphorylcholine and anti-oxLDL antibody levels in metabolic disease patients. The following patients were enrolled: four patients with familial partial lipodystrophy (all women, mean age 32 years old); three familial hypercholesterolemia patients (one girl, two boys; mean age 13 years); and two Niemann–Pick type B (NP-B) patients (two men, mean age 37.5 years old). Participants received one active dose of a 13-valent conjugated pneumococcal vaccine (Prevenar 13) and were followed-up for four weeks. Four weeks after Prevenar 13 vaccination, no differences were observed in patients’ levels of anti-oxLDL IgM or IgG antibodies. In addition, we observed a reduction in anti-phosphorylcholine (anti-PC) IgM antibody levels, whereas no differences were observed in anti-PC IgG antibody titers. These findings indicate that Prevenar 13 vaccination does not induce an immune response against oxLDL in patients with metabolic diseases. Therefore, Prevenar 13 is not suited to target the metabolic disruptor and pro-inflammatory mediator oxLDL in patients. MDPI 2021-01-18 /pmc/articles/PMC7831333/ /pubmed/33477615 http://dx.doi.org/10.3390/antiox10010129 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shiri-Sverdlov, Ronit dos Reis, Inês Magro Oligschlaeger, Yvonne Hendrikx, Tim Meesters, Dennis M. Vanclooster, Annick Vanhoutvin, Nele Koek, Ger H. Westerterp, Marit Binder, Christoph J. Cassiman, David Houben, Tom The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial |
title | The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial |
title_full | The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial |
title_fullStr | The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial |
title_full_unstemmed | The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial |
title_short | The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial |
title_sort | influence of a conjugated pneumococcal vaccination on plasma antibody levels against oxidized low-density lipoprotein in metabolic disease patients: a single-arm pilot clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831333/ https://www.ncbi.nlm.nih.gov/pubmed/33477615 http://dx.doi.org/10.3390/antiox10010129 |
work_keys_str_mv | AT shirisverdlovronit theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT dosreisinesmagro theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT oligschlaegeryvonne theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT hendrikxtim theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT meestersdennism theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT vancloosterannick theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT vanhoutvinnele theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT koekgerh theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT westerterpmarit theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT binderchristophj theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT cassimandavid theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT houbentom theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT shirisverdlovronit influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT dosreisinesmagro influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT oligschlaegeryvonne influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT hendrikxtim influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT meestersdennism influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT vancloosterannick influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT vanhoutvinnele influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT koekgerh influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT westerterpmarit influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT binderchristophj influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT cassimandavid influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial AT houbentom influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial |